A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

被引：0
|
作者：
Neri, Paola [1 ]
Belch, Andrew R. [2 ,3 ]
Johnson, Jordan [1 ]
Gratton, Kathy J. [1 ]
Ren, Li [1 ]
Duggan, Peter [1 ]
Mansoor, Adnan [4 ]
Stewart, Douglas A. [1 ]
Bahlis, Nizar [1 ]
机构：
[1] Univ Calgary, So Alberta Canc Res Inst, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Calgary, Div Hematol & Transfus Med, Calgary, AB, Canada
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：451 / 451
页数：1
相关论文
共 50 条
  • [1] Lenalidomide Induces A Ribosomal Stress Response In Multiple Myeloma (MM) Cells
    Slaby, Jiri
    Tagoug, Ines
    Neri, Paola
    Simms, Justin
    Babich, Jacquelyn
    Gratton, Kathy
    Ren, Li
    Bahlis, Nizar J.
    BLOOD, 2013, 122 (21)
  • [2] A polygenic risk score for multiple myeloma risk prediction
    Federico Canzian
    Chiara Piredda
    Angelica Macauda
    Daria Zawirska
    Niels Frost Andersen
    Arnon Nagler
    Jan Maciej Zaucha
    Grzegorz Mazur
    Charles Dumontet
    Marzena Wątek
    Krzysztof Jamroziak
    Juan Sainz
    Judit Várkonyi
    Aleksandra Butrym
    Katia Beider
    Niels Abildgaard
    Fabienne Lesueur
    Marek Dudziński
    Annette Juul Vangsted
    Matteo Pelosini
    Edyta Subocz
    Mario Petrini
    Gabriele Buda
    Małgorzata Raźny
    Federica Gemignani
    Herlander Marques
    Enrico Orciuolo
    Katalin Kadar
    Artur Jurczyszyn
    Agnieszka Druzd-Sitek
    Ulla Vogel
    Vibeke Andersen
    Rui Manuel Reis
    Anna Suska
    Hervé Avet-Loiseau
    Marcin Kruszewski
    Waldemar Tomczak
    Marcin Rymko
    Stephane Minvielle
    Daniele Campa
    European Journal of Human Genetics, 2022, 30 : 474 - 479
  • [3] A polygenic risk score for multiple myeloma risk prediction
    Canzian, Federico
    Piredda, Chiara
    Macauda, Angelica
    Zawirska, Daria
    Andersen, Niels Frost
    Nagler, Arnon
    Zaucha, Jan Maciej
    Mazur, Grzegorz
    Dumontet, Charles
    Watek, Marzena
    Jamroziak, Krzysztof
    Sainz, Juan
    Varkonyi, Judit
    Butrym, Aleksandra
    Beider, Katia
    Abildgaard, Niels
    Lesueur, Fabienne
    Dudzinski, Marek
    Vangsted, Annette Juul
    Pelosini, Matteo
    Subocz, Edyta
    Petrini, Mario
    Buda, Gabriele
    Razny, Malgorzata
    Gemignani, Federica
    Marques, Herlander
    Orciuolo, Enrico
    Kadar, Katalin
    Jurczyszyn, Artur
    Druzd-Sitek, Agnieszka
    Vogel, Ulla
    Andersen, Vibeke
    Reis, Rui Manuel
    Suska, Anna
    Avet-Loiseau, Herve
    Kruszewski, Marcin
    Tomczak, Waldemar
    Rymko, Marcin
    Minvielle, Stephane
    Campa, Daniele
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (04) : 474 - 479
  • [4] Developing a prediction model for response to lenalidomide treatment in refractory/relapsed multiple myeloma patients
    Chung, Y-J.
    Yim, S-H.
    Jung, S-H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS).
    Sanfilippo, Kristen Marie
    Wang, Tzu-Fei
    Luo, Suhong
    Carson, Kenneth Robert
    Thomas, Theodore Seth
    Gage, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Lenalidomide Treatment of Multiple Myeloma (MM) and Other Neoplasms
    Martinez, Pablo del Pino
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 33 - 36
  • [7] External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients
    Covut, Fahrettin
    Ahmed, Ramsha
    Samaras, Christy J.
    Anwer, Faiz
    Garcia, Alex V. Mejia
    Angelini, Dana E.
    Faiman, Beth M.
    Reed, Janice
    Karam, Mary Ann
    Schlueter, Kristen
    Mathur, Saveta
    Hamilton, Kimberly
    Rosko, Nathaniel
    Valent, Jason
    Khouri, Jack
    BLOOD, 2019, 134
  • [8] Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
    Patel, Krina K.
    Manasanch, Elisabet E.
    Lee, Hans C.
    Ye, J. Christine
    Thomas, Sheeba K.
    Weber, Donna M.
    Becnel, Melody R.
    Gaballa, Mahmoud R.
    Bansal, Hima
    Berkova, Zuzana
    Neelapu, Sattva S.
    Haymaker, Cara L.
    Dang, Minghao
    Wang, Linghua
    Lizee, Greg
    Orlowski, Robert Z.
    BLOOD, 2024, 144 : 4737 - 4738
  • [9] Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients-Report of the Polish Myeloma Group
    Usnarska-Zubkiewicz, L.
    Debski, J.
    Butrym, A.
    Legiec, W.
    Hus, M.
    Dmoszynska, A.
    Stella-Holowiecka, B.
    Zaucha, J. M.
    Januszczyk, J.
    Rymko, M.
    Torosian, T.
    Charlinski, G.
    Lech-Maranda, E.
    Malenda, A.
    Jurczyszyn, A.
    Urbariska-Rys, H.
    Druzd-Sitek, A.
    Blonska, D.
    Urbanowicz, A.
    Holojda, J.
    Pogrzeba, J.
    Rzepecki, P.
    Halka, J.
    Subocz, E.
    Becht, R.
    Zdziarska, B.
    Dytfeld, D.
    Nowicki, A.
    Bolkun, L.
    Kloczko, J.
    Knopinska-Posluszny, W.
    Zubkiewicz-Kucharska, A.
    Kuliczkowski, K.
    LEUKEMIA RESEARCH, 2016, 40 : 90 - 99
  • [10] Adherence to Lenalidomide in Older Patients with Multiple Myeloma (MM): A SEER-Medicare Analysis
    Wildes, Tanya
    Fiala, Mark A.
    Vij, Ravi
    BLOOD, 2017, 130
12345